Re: New Nanobacteria Blood & Semen Tests
- From: no@xxxxxxxx (jrh)
- Date: Thu, 27 Oct 2005 07:50:48 GMT
In article <1130343842.807744.212930@xxxxxxxxxxxxxxxxxxxxxxxxxxxx>,
gmezo@xxxxxxxxxxxxxx says...
>Nanobac Introduces New Improved ELISA Kits for Detection of Calcifying
>Nano-Particles, also known as Nanobacteria
>10/26/2005 8:00:00 AM EST
>Nanobac Life Sciences, Inc. (OTCBB: NNBP) ("Nanobac" or "the Company")
>announced today the introduction of two new versions of its
>NANOCAPTURE(TM) and NANO-SERO(TM) ELISA test kits for the detection of
>Calcifying Nano-Particles (CNPs), also known as nanobacteria, in serum
>or plasma. The new kits offer improved sensitivity, lower background
>and improved stability over the previous versions. Nanobac has added
>new standards to improve precision at the low end and freeze dried the
>critical components for improved stability.
>"Our demand for CNP diagnostic products is increasing as CNP's or
>nanobacteria are implicated in more and more chronic diseases," stated
>Grant Carlson, Nanobac's President and Chief Operating Officer.
>"Nanobac has worked hard to develop robust, sensitive and reproducible
>ELISA test kits for the CNP/nanobacteria research community. These kits
>are CE marked and ready for immediate shipment throughout the European
>Union. In the United States the kits will be sold For Research Use Only
>(RUO)."
>The NANOCAPTURE ELISA is a two-site immunoenzymatic assay for the
>quantitative measurement of CNP/nanobacterial antigen in serum or
>plasma. The NANO-SERO ELISA is also a two site immunoenzymatic assay
>for the quantitative measurement of anti-CNP antibodies in serum or
>plasma. Nanobac will feature the NANOCAPTURE and NANO-SERO ELISA test
>kits at the world's #1 medical trade show, MEDICA, in Dusseldorf,
>Germany, November 16-19, 2005. Last year the show attracted 136,000
>visitors from around the world. Nanobac intends to meet with potential
>customers and establish its global network of in vitro diagnostic
>distributors.
>About Nanobac Life Sciences
>Nanobac Life Sciences, Inc. is a broad-based life science company that
>discovers, develops, manufactures, and markets a range of products and
>services to improve people's health through the detection and treatment
>of Calcifying Nano-Particles, otherwise known as "nanobacteria". The
>Company's pioneering research is establishing the pathogenic role of
>nanobacteria in soft tissue calcification, particularly in coronary
>artery heart disease, prostatitis and vascular disease.
>Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and
>reagents for the detection of Calcifying Nano-Particles. IVD products
>include the NANOCAPTURE(TM) and NANO-SERO(TM) ELISA assays and the
>Nano-Vision(TM) line of antibodies and reagents. Nanobac's
>BioAnalytical Services works with biopharmaceutical partners to develop
>and apply methods for avoiding, detecting, and inactivating or
>eliminating CNPs from raw materials. Nanobac's Drug Discovery and
>Development efforts are focused on developing new and existing
>compounds that effectively inhibit, destroy or neutralize CNPs. The
>Company also markets Dietary Supplements through its subsidiary,
>Nanobac Sciences, LLC.
>Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For
>more information, please visit our website at: http://www.nanobac.com.
>Investors are cautioned that certain statements contained in this
>document as well as some statements in periodic press releases and some
>oral statements of Nanobac Life Sciences, Inc. officials are
>"Forward-Looking Statements" within the meaning of the Private
>Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking
>statements include statements which are predictive in nature, which
>depend upon or refer to future events or conditions, which include
>words such as "believes," "anticipates," "intends," "plans," "expects,"
>and similar expressions. In addition, any statements concerning future
>financial performance (including future revenues, earnings or growth
>rates), ongoing business strategies or prospects, and possible future
>Nanobac Life Sciences, Inc. actions, which may be provided by
>management, are also forward-looking statements as defined by the Act.
>Forward-Looking statements involve known and unknown risks,
>uncertainties, and other factors which may cause the actual results,
>performance or achievements of the Company to materially differ from
>any future results, performance or achievements expressed or implied by
>such forward-looking statements and to vary significantly from
>reporting period to reporting period. Although management believes that
>the assumptions will, in fact, prove to be correct or that actual
>future results will not be different from the expectations expressed in
>this report. These statements are not guarantees of future performance
>and Nanobac Life Sciences, Inc. has no specific intention to update
>these statements.
>CONTACT:
>Nanobac Life Sciences, Inc. John Stanton, CEO or Grant Carlson,
>President/COO
>Telephone: (813) 264-2241
>Website: www.nanobaclabs.com
Interesting
jrh
.
- References:
- New Nanobacteria Blood & Semen Tests
- From: nanobiotech reviews
- New Nanobacteria Blood & Semen Tests
- Prev by Date: Uretritis
- Next by Date: Re: Uretritis
- Previous by thread: New Nanobacteria Blood & Semen Tests
- Next by thread: Uretritis
- Index(es):
Relevant Pages
|
